The development of human recombinant B-type natriuretic peptide for the treatment of decompensated heart failure / 医学研究生学报

ABSTRACT

Human recombinant B type natriuretic peptide(hBNP) binds to receptor in the vasculature, kidney, and other organs to mimic the action of endogenous natriuretic peptides. Intravenous infusion of hBNP has been studied with acute decompensated heart failure. It causes potent, dose related vasodilation that is rapid in onset and sustained for the duration of drug infusion, reflected by decreases in systemic vascular resistance, systemic arterial pressure, pulmonary capillary wedge pressure, right atrial pressure, and mean pulmonary arterial pressure. Vasodilation occurs without a change in heart rate and is associated with increases in stroke volume and cardiac output. hBNP may promote diuresis because of a direct natriuretic action, increased cardiac output, and decreased aldosterone levels. For decompensated heart failure, hBNP improves symptoms and is well tolerated. The major adverse effect is dose related hypotension. As a new vasodilator, it should be valuable in treatment of patients hospitalized for decompensated heart failure.